0001193125-26-193004
SEC filingGlaukos reports 41% net sales growth to $150.6M, cash and investments of $276.7M, no long-term debt, and $6.3M in minimum purchase commitments.
As of March 31, 2026, Glaukos held $104.2M in cash and cash equivalents and $172.4M in short-term investments, totaling $276.6M in liquidity. Total assets were $893.3M, with stockholders' equity of $670.9M. The company has no long-term debt aside from finance lease liabilities of $67.7M and operating lease liabilities of $35.3M. Inventory was $62.4M, slightly down from $63.6M at year-end 2025.
Glaukos has a minimum compensation commitment of $6.3M payable over four years under a supply agreement with Celanese for iDose TR raw materials. Additionally, the company has an Option Agreement with a biopharmaceutical company for up to $17.5M upfront, but no payments are currently probable. Contingent consideration liabilities from acquisitions total $8.7M, primarily related to Mobius. Lease commitments for operating and finance leases are $60.8M and $112.1M respectively, including options reasonably certain to be exercised.
No share buybacks or dividends were declared during the quarter. Capital expenditures were $4.0M (2.6% of sales), primarily for property and equipment. Stock-based compensation was $19.1M, a 47% increase YoY, with $86.3M in total unamortized expense remaining.
The company operates as a single segment but discloses revenue by product category and geography. Glaucoma product revenues grew 46.7% YoY to $129.3M, driven by iDose TR and iStent. Corneal Health revenues rose 15.0% to $21.3M, with the controlled commercial launch of Epioxa underway. U.S. sales comprised $112.3M (74.6%) and international $38.2M (25.4%).
The provided document excerpt does not contain the actual consolidated statements of cash flows. Only a reconciliation of cash, cash equivalents, and restricted cash is presented, showing a net increase of $13.4 million (from $94.6M at Dec 31, 2025 to $108.1M at Mar 31, 2026). Without operating, investing, and financing activity details, no meaningful cash flow quality analysis can be performed. The filing appears to be missing the key cash flow statement data required for this task.